Dr Manoj Kumar, senior cardiologist at Max Hospital, New Delhi speaking to ANI on Saturday. (Photo/ANI)
30 crore people to be vaccinated against COVID-19 in first phase: Max hospital Cardiologist ANI | Updated: Jan 03, 2021 06:03 IST
New Delhi [India], January 3 (ANI): As the country is eagerly waiting for the COVID-19 vaccination programme to begin, Dr Manoj Kumar, senior cardiologist at Max Hospital, New Delhi said that in the first phase, almost 30 crore population will be covered. Recently, the Drugs Controller General of India (DCGI) has approved the Serum Institute of India (SII) vaccine Covishield. There is also the possibility that COVAXIN of Bharat Biotech will be approved. This is good news in New Year. In the initial phase, they have planned to vaccinate one crore healthcare workers and two crore frontline corona warriors. In the first phase of vaccination, they are planning to vaccinate almost 30 crore population Dr Kumar told
New Delhi [India], January 3 (ANI): Senior Congress leader Shashi Tharoor on Sunday said that the emergency approval to COVID-19 vaccine Covaxin is premature and could be dangerous as it is still under phase 3 trial. He urged Union Health Minister Dr Harsh Vardhan to wait till full trials of the vaccine are completed.
Read more about Post expert committee recommendation, DCGI to brief media today on vaccine on Business Standard. As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of the accelerated approval process request of the SII
COVID-19 vaccine in India: It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, said PM Mo
Congress leader Shashi Tharoor said that the approval was premature and could be dangerous. Covishield by SII and Covaxin by Bharat Biotech got the DCGI nod for restricted use .
New Delhi: The Drugs Controller General of India (DCGI) on Sunday granted emergency use approval to Serum Institute of India (SII) and Bharat Biotech for their COVID-19 vaccines. Covishield by SII and Covaxin by Bharat Biotech got the DCGI nod for restricted use .
Congratulating the country over the same, Prime Minister Narendra Modi said: A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators.